XML 131 R114.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Product Information [Line Items]      
Revenues $ 15,846 $ 14,925 $ 15,878
North America [Member]      
Product Information [Line Items]      
Revenues 8,124 7,452 7,809
Europe [Member]      
Product Information [Line Items]      
Revenues 4,837 4,525 4,886
International Markets [Member]      
Product Information [Line Items]      
Revenues 1,958 1,903 2,032
Generic products [Member] | North America [Member]      
Product Information [Line Items]      
Revenues 3,475 3,549 3,769
Generic products [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 3,664 3,466 3,569
Generic products [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 1,594 1,586 1,649
AJOVY [Member] | North America [Member]      
Product Information [Line Items]      
Revenues 230 218 176
AJOVY [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 160 124 87
AJOVY [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 44 35 50
AUSTEDO [Member] | North America [Member]      
Product Information [Line Items]      
Revenues 1,225 963 802
BENDEKA and TREANDA [Member] | North America [Member]      
Product Information [Line Items]      
Revenues 241 316 385
COPAXONE [Member] | North America [Member]      
Product Information [Line Items]      
Revenues 320 387 577
COPAXONE [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 231 268 391
COPAXONE [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 39 36 37
Anda [Member] | North America [Member]      
Product Information [Line Items]      
Revenues 1,577 1,471 1,323
Respiratory Product [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 265 273 356
Other [Member] | North America [Member]      
Product Information [Line Items]      
Revenues [1] 1,056 549 777
Other [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues [2] 516 393 483
Other [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues $ 281 $ 246 $ 295
[1] Other revenues were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s anti-TL1A asset. See note 2.
[2] Other revenues in 2023 were mainly related to the sale of certain product rights.